The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and mitigate supply chain vulnerabilities, including collaborating with the private sector to develop and implement programs to assess and incentivize resiliency in manufacturer and hospital purchasing behavior. The paper focuses on generic sterile injectable medicines used in inpatient settings, citing their importance and relative risk of supply disruptions.

Headline
The Administration for Strategic Preparedness and Response announced Nov. 3 that it will partner with the Bureau of Industry and Security and the Assistant…
Headline
The Department of Health and Human Services Sept. 18 announced the launch of a new personal protective equipment forecast to identify, consolidate and publish…
Headline
The Centers for Medicare & Medicaid Services’ six-month moratorium on the enrollment of new durable medical equipment, prosthetics, orthotics and supply…
Headline
The U.S. Trade Representative yesterday announced it is implementing a 10% or 12.5% tariff on 60 trading partners, which became effective today. These…
Headline
The Food and Drug Administration July 10 released a proposed rule that would modernize drug establishment registration requirements, with implications for…
Headline
The AHA today sent a letter to the Office of the United States Trade Representative to ask that medications, medical devices and other healthcare…